Jikeqin’s marketing application accepted by the drug regulatory authority
February 26, 2026
Source: drugdu
25
On February 25, Jiuyuan Gene (02566) issued an announcement stating that the marketing application of its developed product, Jikeqin®, has been accepted by the National Medical Products Administration of the People's Republic of China.
This product is a biosimilar of the long-acting glucagon-like peptide receptor agonist smegglutide, designed for weight management in obese or overweight individuals.
Glucose control and weight management are achieved by mimicking the physiological effects of endogenous GLP-1 hormones, which promote insulin secretion, inhibit glucagon release, suppress appetite, and delay gastric emptying.
In the ongoing Phase III clinical trials, the clinical equivalence study of clopidogrel in obese subjects showed that its primary efficacy endpoint (the rate of change in weight from baseline after 44 weeks of treatment) and safety were clinically equivalent to the reference drug, demonstrating good efficacy and tolerability.
https://finance.eastmoney.com/a/202602263654818764.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Qilu Pharmaceutical achieves another breakthrough in internationalization, with its blockbuster anti-tumor drug bevacizumab approved for marketing in the UK. February 26, 2026
- Etoposide Injection and Fluorouracil Injection Receive FDA Approval in the United States February 26, 2026
- Net profit surged by 1041%, marking a breakthrough for the self-exempt king February 26, 2026
- Kanghong Pharmaceutical’s Class 1 new drug receives clinical trial approval February 26, 2026
- Bio-Thera Solutions’ innovative drug, Darpubayimab injection, has had its marketing authorization application accepted by the NMPA February 25, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
